Table 1.

Dose modifications for hematological toxicities.

Worst toxicity by CTCAE grade	Nal-IRI	5-FU	Oxaliplatin
Grade 2 neutropenia (ANC <1500–1000 cells/mm3)	100% of previous dose	100% of previous dose	1st occurrence: 100% of previous dose; 2nd occurrence: reduce dose to 50 mg/m2
Grade 3 or 4 neutropenia (ANC <1000/mm3) or febrile neutropenia	1st occurrence: reduce dose to 40 mg/m2; 2nd occurrence: reduce dose to 30 mg/m2	1st occurrence: reduce dose by 25%; 2nd occurrence: reduce dose another 25% (50% of original dose)	1st occurrence: 100% of previous dose; 2nd occurrence: reduce dose to 50 mg/m2
>Grade 2 thrombocytopenia (Grade 2: platelets <75,000–50,000/mm3 OR Grade 3–4: platelets <50,000/mm3)	If grade 2: 100% of previous dose If >grade 3: 1st occurrence: reduce dose to 50 mg/m2; 2nd occurrence: reduce dose to 40 mg/m2	If grade 2: 100% of previous dose If >grade 3: 1st occurrence: reduce dose by 25%; 2nd occurrence: reduce dose another 25% (50% of original dose)	1st occurrence: reduce dose to 60 mg/m2; 2nd occurrence: maintenance of the reduced dose of 50 mg/m2
Other hematological toxicities not specifically listed above	If <grade 2: 100% of previous dose If >grade 3: 1st occurrence: reduce dose to 40 mg/m2; 2nd occurrence: reduce dose to 30 mg/m2	If <grade 2: 100% of previous dose If >grade 3: 1st occurrence: reduce dose by 25%; 2nd occurrence: reduce dose another 25% (50% of original dose)	If <grade 2: 100% of previous dose If >grade 3: 1st occurrence: reduce dose to 50 mg/m2; 2nd occurrence: maintenance of the reduced dose of 50 mg/m2

ANC, absolute neutrophil count; CTCAE, common toxicities adverse events criteria; 5-FU, 5-fluorouracil; Nal-IRI, nanoliposomal irinotecan.